Neuroscience Clinical Development Experts

Cognitive Research Corporation (CRC) is a full-service CRO with deep expertise in CNS/Neuro drug development from Phase I to Phase IV. Our Team’s neuro-focused experience and lessons learned allows us to focus on clinical trial operational excellence that provides our Sponsors improved patient experiences, accelerated timelines, reduced costs, quality-driven data, and milestone adherence for better outcomes and a shared vision. 

Connect with CRC

Leading Phase I-IV
Neuroscience-specialty CRO

Cognitive Research Corporation (CRC) is a privately held, full-service contract research organization that specializes in Neuroscience product development for pharmaceutical, nutraceutical, biotechnology and medical device companies. We combine a deep scientific understanding of the Neuroscience space with decades of operational experience in managing clinical trials around the globe. It is personal to CRC, and it is personal to every member of our team. We Change Lives.

Our scientific expertise has resulted in more than 200+ clinical trials across 30+ INDs and 14 NDA submissions and approvals. Our focused, Neuroscience expertise has allowed us to build strong relationships with the leading Neuro/CNS research sites to provide the strongest candidates to complete our programs. Our partner network includes 300+ clinical research sites that are fully equipped and trained to conduct CRC clinical trials.

Our mission is to continue to be the most trusted, customer-centric, Neuroscience-focused clinical services company; Our Vision, a world where most of today’s cognitive health challenges can be effectively treated or even cured so that patients have a chance at a better quality of life.

Our Expertise

Psychometric Technology

Learn More

Therapeutic Expertise

Learn More

CRO Services

Learn More

NEWS

Stay up to date on our newest trials, events and industry news!

  • Two FDA Approvals to Advance Migraine Care
  • CRC Expands Medical Leadership Team with Appointment of Accomplished Medical Directors
  • IND to FDA Approval: Acute Agitation in Schizophrenia and Bipolar Disorders

Looking for study info?

Ready to submit an RFP? Reach out to get started!

Annie Speno

VP, Business Development